Roman Architecture (HSAR 252) Professor Kleiner discusses the increasing size of Roman architecture ...
As Director of Design
Sizing up the future of the European Union (Without the UK!)
Over the past four decades not only has the Association of South East Asian Nations managed to conta...
Watch Thursdays at 9pm only on the Science Channel. sciencechannel.com
PlosMedicine |
(0) (0 Votes)
|
Views: (184) Date: (02-06-09) Pages: () |
Abstract: An important emerging issue in health care is the availability of medications to treat what until recently have been regarded as the natural results of aging or as part of the normal range of human emotions. Thus, we now see treatments widely advertised for male pattern baldness and shyness. Deviating even further, drug therapy is moving out of treating diseases to providing enhancements to what had hitherto been seen as normal functioning. This evolution in the use of medications has introduced dilemmas and controversies about what are legitimate conditions and treatments for those concerned with prescription medications: is any deviation from normality fair game for treatment? What about people who have nothing medically wrong with them, but just want to feel better? Who will pay for these therapies, and what are the implications for the way we use health-care resources? Medica tions that embody these controversies are generally referred to as lifestyle drugs and perhaps the best known of these is sildenafil citrate (Viagra) This article will examine the strategies used by Pfizer, the maker of Viagra, to ensure that the drug was seen as legitimate therapy for almost any man. Pfizer took steps to make sure that Viagra was not relegated to a niche role of just treating men who had ED due to organic causes, such as diabetes or prostate surgery. Citation : Lexchin J (2006) Bigger and Better: How Pfizer Redefined Erectile Dysfunction. PLoS Med 3(4): e132. doi:10.1371/journal. pmed.0030132